Compare Entergy Corporation (ETR) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entergy Corporation vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Entergy Corporation trades at $103.92 (market cap $50.16B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Entergy Corporation is far larger — about 51.6× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Entergy Corporation pays a 2.44% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Entergy Corporation for 13 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| ETR | MRVI | |
|---|---|---|
Market Cap | $50.16B | $972.90M |
Volume | 2,603,991 | 4,325,710 |
Sector | Utilities | Health |
52-Week High | $117.91 | $9.00 |
52-Week Low | $91.19 | $2.83 |
Typical Hold Time | 13 Days | 0 Days |
Enterprise Value | $80.94B | $1.08B |
Dividend Yield | 2.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Entergy Corporation (ETR) trades at $104.99, up 0.96% with a bullish technical signal despite overbought RSI readings. The stock shows strong fundamentals with 13.48% net margins and consistent earnings beats in recent quarters. Recent developments include $13.7M in federal grid funding and new data center agreements benefiting customers. Analyst consensus remains strongly positive with 59% buy ratings and a $123.17 price target representing 17% upside potential.
ETR presents a compelling investment case with stable utility operations, improving cash flows, and strategic grid investments. However, elevated valuation multiples and institutional selling activity warrant caution. The stock's proximity to resistance at $105 suggests near-term consolidation may precede further gains if earnings momentum continues through Q3 results.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entergy Corporation
Entergy is an energy company that operates regulated electric utilities and power generation businesses in the United States. Its generation portfolio includes nuclear, natural gas, and renewable resources.
Read more on ETR →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
